Investigation of recombinant human insulin-like growth factor type I in thymus regeneration in the acute stage of experimental FIV infection in juvenile cats

AIDS Research and Human Retroviruses

Volumn 15, Issue 15, 1999, Pages 1377-1388

  Woo, Jennifer C ^a   Dean, Gregg A ^b   Lavoy, Alora ^b   Clark, Ross ^c,d   Moore, Peter F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; RECOMBINANT SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAT; CELL MATURATION; CONTROLLED STUDY; DISEASE COURSE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; T LYMPHOCYTE; THYMUS; THYMUS FUNCTION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0033544011     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310089     Document Type: Article

References (62)

1. McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB, Francis IR, Gross BH, and Grant RM: High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998;101(11):2301-2308. [See Comments]
2. Nahmias AJ, Clark WS, Kourtis AP, Lee FK, Cotsonis G, Ibegbu C, Thea D, Palumbo P, Vink P, Simonds RJ, and Nesheim SR: Thymic dysfunction and time of infection predict mortality in human immunodeficiency virus-infected infants. CDC Perinatal AIDS Collaborative Transmission Study Group. J Infect Dis 1998;178(3):680-685.
3. Braun J, Valentin H, Nugeyre MT, Ohayon H, Gounon P, and Barré-Sinoussi F: Productive and persistent infection of human thymic epithelial cells in vitro with HIV-1. Virology 1996; 225(2):413-418.
4. Rothe M, Chene L, Nugeyre MT, Braun J, Barré-Sinoussi F, and Israel N: Contact with thymic epithelial cells as a prerequisite for cytokine-enhanced human immunodeficiency virus type 1 replication in thymocytes. J Virol 1998;72(7):5852-5861.
5. Uittenbogaart CH, Anisman DJ, Jamieson BD, Kitchen S, Schmid I, Zack JA, and Hays EF: Differential tropism of HIV-1 isolates for distinct thymocyte subsets in vitro. AIDS 1996;10(7):F9-16.
6. Beaulieu S, Lafontaine M, Richer M, Courchesne I, Cohen EA, and Bergeron D: Characterization of the cytotoxic factor(s) released from thymic dendritic cells upon human immunodeficiency virus type 1 infection. Virology 1998;241(2):285-297.
7. Kitchen SG, Uittenbogaart CH, and Zack JA: Mechanism of human immunodeficiency virus type 1 localization in CD4-negative thymocytes: Differentiation from a CD4-positive precursor allows productive infection. J Virol 1997;71(8):5713-5722.
8. Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, McCune JM, and Kaneshima H: HIV induces thymus depletion in vivo. Nature (London) 1993;363(6431):728-732.
9. Calabro ML, Zanotto C, Calderazzo F, Crivellaro C, Del Mistro A, De Rossi A, and Chieco-Bianchi L: HIV-1 infection of the thymus: evidence for a cytopathic and thymotropic viral variant in vivo. AIDS Res Hum Retroviruses 1995;11(1):11-19.
10. Kourtis AP, Ibegbu C, Nahmias AJ, Lee FK, Clark WS, Sawyer MK, and Nesheim S: Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 1996;335(19): 1431-1436. [Published erratum appears in N Engl J Med 1997; 336(8):595]
11. Rosenzweig M, Clark DP, and Gaulton GN: Selective thymocyte depletion in neonatal HIV-1 thymic infection. AIDS 1993;7(12): 1601-1605.
12. Su L, Kaneshima H, Bonyhadi M, Salimi S, Kraft D, Rabin L, and McCune JM: HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity 1995;2(1):25-36.
13. Joshi VV: Pathology of acquired immunodeficiency syndrome (AIDS) in children. Keio J Med 1996;45(4):306-312.
14. Quijano G, Siminovich M, and Drut R: Histopathologic findings in the lymphoid and reticuloendothelial system in pediatric HIV infection: A postmortem study. Pediatr Pathol Lab Med 1997; 17(6):845-856.
15. Gray CM, Schapiro JM, Winters MA, and Merigan TC: Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998;14(7):561-569.
16. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St. Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, and Kessler H: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178(1):70-79.
17. Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, Lange JM, Miedema F, Danner SA, and Schellekens PT: Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16(5):318-326.
18. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, and Schellekens PT: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nature Med 1998;4(2):208-214. [See comments]
19. Silvestri G, Munoz-Calleja C, Bagnarelli P, Piedimonte G, Clementi M, and Montroni M: Early increase of CD4+CD45RA+ and CD4+CD95-cells with conserved repertoire induced by antiretroviral therapy in HIV-infected patients. Clin Exp Immunol 1998;111(1):3-11.
20. Tapson VF, Boni-Schnetzler M, Pilch PF, Center DM, and Berman JS: Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J Clin Invest 1988;82(3):950-957.
21. Monroe WE, Roth JA, Grier RL, Arp LH, and Naylor PH: Effects of growth hormone on the adult canine thymus. Thymus 1987; 9(3):173-187.
22. Morrison WB, Goff BL, Stewart-Brown B, Incefy GS, Arp LH, and Roth JA; Orally administered clonidine as a secretagogue of growth hormone and as a thymotrophic agent in dogs of various ages. Am J Vet Res 1990;51(1):65-70.
23. Sabharwal P and Varma S: Growth hormone synthesized and secreted by human thymocytes acts via insulin-like growth factor I as an autocrine and paracrine growth factor. J Clin Endocrinol Metab 1996;81(7):2663-2669.
24. Savino W, de Mello-Coelho V, and Dardenne M: Control of the thymic microenvironment by growth hormone/insulin-like growth factor-I-mediated circuits. Neuroimmunomodulation 1995;2(6): 313-318.
25. Yamada M, Hato F, Kinoshita Y, Tominaga K, and Tsuji Y: The indirect participation of growth hormone in the thymocyte proliferation system. Cell Mol Biol (Noisy-le-Grand) 1994;40(2): 111-121.
26. Bercu BB, Walker RF, and Serono Symposia U: Growth Hormone, Vol. II: Basic and Clinical Aspects. Springer-Verlag, New York, 1994.
27. Kozak RW, Haskell JF, Greenstein LA, Rechler MM, Waldmann TA, and Nissley SP: Type I and II insulin-like growth factor receptors on human phytohemagglutinin-activated T lymphocytes. Cell Immunol 1987;109(2):318-331.
28. Stuart CA, Meehan RT, Neale LS, Cintron NM, and Furlanetto RW: Insulin-like growth factor-I binds selectively to human peripheral blood monocytes and B-lymphocytes. J Clin Endocrinol Metab 1991;72(5):1117-1122.
29. Kooijman R, Willems M, De Haas CJ, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, Heijnen CJ, and Zegers BJ: Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology 1992;131(5):2244-2250.
30. Xu X, Mardell C, Xian CJ, Zola H, and Read LC: Expression of functional insulin-like growth factor-1 receptor on lymphoid cell subsets of rats. Immunology 1995;85(3):394-399.
31. Hartmann KK, Baier TG, Papa V, Kronenwett M, Brown EJ, Goldfine ID, and Rosenthal SM: A monoclonal antibody to the T-cell receptor increases IGF-I receptor content in normal T-lymphocytes: Comparison with phytohemagglutinin. J Cell Biochem. 1992;48(1):81-85.
32. Schillaci R, Ribaudo CM, Rondinone CM, and Roldan A: Role of insulin-like growth factor-1 on the kinetics of human lymphocytes stimulation in serum-free culture medium. Immunol Cell Biol 1994;72(4):300-305.
33. Clark R, Strasser J, McCabe S, Robbins K, and Jardieu P: Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest 1993;92(2):540-548.
34. Kimata H and Yoshida A: Effect of growth hormone and insulin-like growth factor-I on immunoglobulin production by and growth of human B cells. J Clin Endocrinol Metab 1994;78(3):635-641.
35. Robbins K, McCabe S, Scheiner T, Strasser J, Clark R, and Jardieu P: Immunological effects of insulin-like growth factor-I - enhancement of immunoglobulin synthesis. Clin Exp Immunol 1994;95(2):337-342.
36. Ellis KJ, Lee PD, Pivarnik JM, Bukar JG, and Gesundheit N: Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone. J Clin Endocrinol Metab 1996;81(8):3033-3038.
37. Frost RA, Nachman SA, Lang CH, and Gelato MC: Proteolysis of insulin-like growth factor-binding protein-3 in human immunodeficiency virus-positive children who fail to thrive. J Clin Endocrinol Metab 1996;81(8):2957-2962.
38. Hirschfeld S: Use of human recombinant growth hormone and human recombinant insulin-like growth factor-I in patients with human immunodeficiency virus infection. Hormone Res 1996; 46(4-5):215-221.
39. Lee PD, Pivarnik JM, Bukar JG, Muurahainen N, Berry PS, Skolnik PR, Nerad JL, Kudsk KA, Jackson L, Ellis KJ, and Gesundheit N: A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996;81(8):2968-2975. [Published erratum appears in J Clin Endocrinol Metab 1996;81(10):3696]
40. Frost RA, Fuhrer J, Steigbigel R, Mariuz P, Lang CH, and Gelato MC: Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol 1996;44(5):501-514.
41. Heijligenberg R, Sauerwein HP, Brabant G, Endert E, Hommes MJ, and Romijn JA: Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996;81(11): 4028-4032.
42. Matarazzo P, Palomba E, Lala R, Ciuti E, Altare F, de Sanctis L, and Tovo PA: Growth impairment, IGF I hyposecretion and thyroid dysfunction in children with perinatal HIV-1 infection. Acta Paediatr 1994;83(10):1029-1034.
43. Grinspoon S, Corcoran C, Lee K, Burrows B, Hubbard J, Katznelson L, Walsh M, Guccione A, Cannan J, Heller H, Basgoz N, and Klibanski A: Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996; 81(11):4051-4058.
44. Ratner Kaufman F, Gertner JM, Sleeper LA, and Donfield SM: Growth hormone secretion in HIV-positive versus HIV-negative hemophilic males with abnormal growth and pubertal development. The Hemophilia Growth and Development Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(2):137-144.
45. Woo JC, Dean GA, Pedersen NC, and Moore PF: Immunopathologic changes in the thymus during the acute stage of experimentally induced feline immunodeficiency virus infection in juvenile cats. J Virol 1997;71(11):8632-8641.
46. Dua N, Reubel G, Moore PF, Higgins J, and Pedersen NC: An experimental study of primary feline immunodeficiency virus infection in cats and a historical comparison to acute simian and human immunodeficiency virus diseases. Vet Immunol Immunopathol 1994;43(4):337-355.
47. Bang P, Baxter RC, Blum WF, Breier BH, Clemmons DR, Hall K, Hintz RL, Holly JM, Rosenfeld RG, and Zapf J: Valid measurements of total IGF concentrations in biological fluids. Recommendations from the 3rd International Symposium on Insulin-like Growth Factors. J Endocrinol 1994;143(3):C1-2.
48. Dean GA, Reubel GH, Moore PF, and Pedersen NC: Proviral burden and infectious kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol 1996; 70(8):5165-5169.
49. Reubel GH, George JW, Higgins J, and Pedersen NC: Effect of chronic feline immunodeficiency virus infection on experimental feline calicivirus-induced disease. Vet Microbiol 1994;39(3-4): 335-351.
50. Bolender RP, Hyde DM, and Dehoff RT: Lung morphometry: A new generation of tools and experiments for organ, tissue, cell, and molecular biology. Am J Physiol 1993;265(6 Pt 1):L521-548.
51. Woo JC and Moore PF: A feline homologue of CD1 is defined using a feline-specific monoclonal antibody. Tissue Antigens 1997;49(3 Pt 1):244-251.
52. Dean GA, Bernales JA, and Pedersen NC: Effect of feline immunodeficiency virus on cytokine response to Listeria monocytogenes in vivo. Vet Immunol Immunopathol 1998;65(2-4):125-138. [In Process Citation]
53. Zachar V, Thomas RA, and Goustin AS: Absolute quantification of target DNA: A simple competitive PCR for efficient analysis of multiple samples. Nucleic Acids Res 1993;21(8):2017-2018.
54. Beebe AM, Dua N, Faith TG, Moore PF, Pedersen NC, and Dandekar S: Primary stage of feline immunodeficiency virus infection: Viral dissemination and cellular targets. J Virol 1994;68(5): 3080-3091.
55. Gaulton GN, Scobie JV, and Rosenzweig M: HTV-1 and the thymus. AIDS 1997;11(4):403-414. [Editorial]
56. Germinario RJ, DeSantis T, and Wainberg MA: Insulin-like growth factor 1 and insulin inhibit HIV type 1 replication in cultured cells. AIDS Res Hum Retroviruses 1995;11(5):555-561.
57. Sharma UK, Song H, Casella SJ, and Schwartz DH: Failure of insulin-like growth factor type 1 to suppress HIV type 1 in adult or umbilical cord mononuclear blood cells. AIDS Res Hum Retroviruses 1997;13(1):105-110.
58. Verland S and Gammeltoft S: Functional receptors for insulin-like growth factors I and II in rat thymocytes and mouse thymoma cells. Mol Cell Endocrinol 1989;67(2-3):207-216.
59. Kooijman R, Scholtens LE, Rijkers GT, and Zegers BJ: Type I insulin-like growth factor receptor expression in different developmental stages of human thymocytes. J Endocrinol 1995;147(2): 203-209.
60. Gjerset RA, Yeargin J, Volkman SK, Vila V, Arya J, and Haas M: Insulin-like growth factor-I supports proliferation of autocrine thymic lymphoma cells with a pre-T cell phenotype. J Immunol 1990;145(10):3497-3501.
61. Douek DC, McFarland RD, Reiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, and Koup RA: Changes in thymic function with age and during the treatment of HIV infection. Nature (London) 1998;396(6712):690-695. [See comments]
62. Sattler F, LoPresti J, Dube M, Montgomery AB, Jardieu P, Spencer C, Saad M, Nicoloft JT, and Clark R: IGF-1 treatment during early HIV infection: Immunological and hormonal effects. In: Molecular Mechanisms to Regulate the Activities of Insulin-Like Growth Factors: Proceedings of the 4th International Symposium on Insulin-like Growth Factors (Takano K, Hizuka N, and Takahashi S, eds.). Elsevier, Amsterdam, 1998, pp. 351-358.